EUVIMEDEUVIMED entdecken
Crossref

The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable‐risk prostate cancer

Avery E Braun iD, June M Chan, John Neuhaus, Janet E Cowan, Stacey A Kenfield iD, Erin L Van Blarigan, Imelda Tenggara, Jeanette M Broering, Jeffry P Simko, Peter R Carroll, Matthew R Cooperberg

Cancer · 2024

DOI: 10.1002/cncr.35215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Avery E Braun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Grading, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The challenge of distinguishing indolent from aggressive prostate cancer (PCa) complicates decision‐making for men considering active surveillance (AS). Genomic classifiers (GCs) may improve risk stratification by predicting end points such as upgrading or upstaging (UG/US). The aim of this study was to assess the impact of GCs on UG/US risk prediction in a clinicopathologic model.

Methods

Participants had favorable‐risk PCa (cT1‐2, prostate‐specific antigen [PSA] ≤15 ng/mL, and Gleason grade group 1 [GG1]/low‐volume GG2). A prediction model was developed for 864 men at the University of California, San Francisco, with standard clinical variables (cohort 1), and the model was validated for 2267 participants from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry (cohort 2). Logistic regression was used to compute the area under the receiver operating characteristic curve (AUC) to develop a prediction model for UG/US at prostatectomy. A GC (Oncotype Dx Genomic Prostate Score [GPS] or Prolaris) was then assessed to improve risk prediction.

Results

The prediction model included biopsy GG1 versus GG2 (odds ratio [OR], 5.83; 95% confidence interval [CI], 3.73–9.10); PSA (OR, 1.10; 95% CI, 1.01–1.20; per 1 ng/mL), percent positive cores (OR, 1.01; 95% CI, 1.01–1.02; per 1%), prostate volume (OR, 0.98; 95% CI, 0.97–0.99; per mL), and age (OR, 1.05; 95% CI, 1.02–1.07; per year), with AUC 0.70 (cohort 1) and AUC 0.69 (cohort 2). GPS was associated with UG/US (OR, 1.03; 95% CI, 1.01–1.06; p < .01) and AUC 0.72, which indicates a comparable performance to the prediction model.

Conclusions

GCs did not substantially improve a clinical prediction model for UG/US, a short‐term and imperfect surrogate for clinically relevant disease outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeoplasm GradingBiomarkers, TumorHumansMaleMiddle AgedAgedRisk AssessmentProstate-Specific AntigenNeoplasm StagingProstatectomyGenomicsROC Curve

Stichwörter der Autor:innen

active surveillancegenomic classifierspredictionprostate cancer

Substanzen

Biomarkers, TumorProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, University of California, San Francisco, California, USA.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
  • Department of Surgery, University of California, San Francisco, California, USA.
  • Department of Pathology, University of California, San Francisco, California, USA.

ORCID-Profile: Avery E Braun, Stacey A Kenfield

Förderung

  • NIH HHS

Zitieren

APA

Braun, A. E., Chan, J. M., Neuhaus, J., Cowan, J. E., Kenfield, S. A., Van Blarigan, E. L., Tenggara, I., Broering, J. M., Simko, J. P., Carroll, P. R., & Cooperberg, M. R. (2024). The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable‐risk prostate cancer. Cancer. https://doi.org/10.1002/cncr.35215

Vancouver

Braun AE, Chan JM, Neuhaus J, Cowan JE, Kenfield SA, Van Blarigan EL, et al. The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable‐risk prostate cancer. Cancer. 2024. doi:10.1002/cncr.35215

BibTeX
@article{Braun2024,
  author = {Braun, Avery E and Chan, June M and Neuhaus, John and Cowan, Janet E and Kenfield, Stacey A and Van Blarigan, Erin L and Tenggara, Imelda and Broering, Jeanette M and Simko, Jeffry P and Carroll, Peter R and Cooperberg, Matthew R},
  title = {The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable‐risk prostate cancer},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35215}
}
Kostenlos starten →